Johnson & Johnson (JNJ) Position Maintained by Bonness Enterprises Inc.
Bonness Enterprises Inc. held its stake in shares of Johnson & Johnson (NYSE:JNJ) during the third quarter, according to its most recent disclosure with the SEC. The fund owned 44,438 shares of the company’s stock at the end of the third quarter. Johnson & Johnson makes up 4.4% of Bonness Enterprises Inc.’s holdings, making the stock its 4th largest position. Bonness Enterprises Inc.’s holdings in Johnson & Johnson were worth $5,250,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of the stock. Americafirst Capital Management LLC bought a new position in shares of Johnson & Johnson during the second quarter worth approximately $101,000. Tuttle Tactical Management LLC bought a new position in shares of Johnson & Johnson during the second quarter worth approximately $103,000. Lenox Wealth Management Inc. increased its position in shares of Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock worth $118,000 after buying an additional 190 shares during the last quarter. Thomas J. Herzfeld Advisors Inc. increased its position in shares of Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock worth $122,000 after buying an additional 690 shares during the last quarter. Finally, NCM Capital Management Group Inc. bought a new position in shares of Johnson & Johnson during the second quarter worth approximately $127,000. Institutional investors and hedge funds own 64.13% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) traded down 1.05% during midday trading on Wednesday, hitting $111.30. The stock had a trading volume of 11,166,987 shares. Johnson & Johnson has a one year low of $94.28 and a one year high of $126.07. The firm’s 50-day moving average price is $115.97 and its 200-day moving average price is $118.40. The firm has a market capitalization of $302.80 billion, a PE ratio of 19.54 and a beta of 0.75.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.66 by $0.02. Johnson & Johnson had a return on equity of 25.30% and a net margin of 22.03%. The firm earned $17.80 billion during the quarter, compared to analysts’ expectations of $17.71 billion. During the same period last year, the firm posted $1.49 EPS. The business’s revenue was up 4.2% on a year-over-year basis. On average, equities analysts predict that Johnson & Johnson will post $6.72 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be issued a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 2.88%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.29. The ex-dividend date is Friday, November 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 56.64%.
A number of research analysts recently commented on JNJ shares. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price objective for the company in a research note on Monday, August 22nd. RBC Capital Markets set a $133.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research note on Wednesday, November 9th. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday, September 20th. Argus restated a “buy” rating and set a $145.00 price objective on shares of Johnson & Johnson in a research note on Friday, October 21st. Finally, BTIG Research restated a “neutral” rating on shares of Johnson & Johnson in a research note on Thursday, August 25th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $121.03.
In other Johnson & Johnson news, Director Charles Prince purchased 875 shares of the company’s stock in a transaction that occurred on Friday, October 21st. The stock was purchased at an average cost of $114.11 per share, with a total value of $99,846.25. Following the acquisition, the director now directly owns 26,520 shares of the company’s stock, valued at approximately $3,026,197.20. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.11% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.